Eli Lilly and Co

$ 115.2 -1.3 (-1.12%)
Volume: 9,805,773 Avg Vol (1m): 21,435,366
Market Cap $: 111.79 Bil Enterprise Value $: 117.56 Bil
P/E (TTM): 37.28 P/B: 12.42
Earnings Power Value -148.33
Net Current Asset Value -12.77
Tangible Book 1.85
Projected FCF 36.58
Median P/S Value 64.05
Graham Number 11.35
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 6/10

Current vs industry vs history
Cash-to-Debt 0.63
Equity-to-Asset 0.22
Debt-to-Equity 1.30
Debt-to-EBITDA 2.25
Interest Coverage 23.63
Piotroski F-Score 7
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.50
DISTRESS
GREY
SAFE
Beneish M-Score -2.36
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 30.72%
WACC 5.3%

Profitability & Growth : 8/10

Current vs industry vs history
Operating Margin % 26.18
Net Margin % 13.16
ROE % 26.68
ROA % 7.34
ROC (Joel Greenblatt) % 42.21
3-Year Total Revenue Growth Rate 7.20
3-Year Total EBITDA Growth Rate 9.00
3-Year EPS w/o NRI Growth Rate 11.50

» LLY's 30-Y Financials

Financials (Next Earnings Date: 2019-04-30)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:LLY

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Major    NAICS : 325412    SIC : 2834
Compare LSE:AZN NYSE:BMY XPAR:SAN LSE:GSK XTER:BAYN TSE:4503 TSE:4519 TSE:4578 NYSE:ABBV TSE:4568 NYSE:MRK HKSE:01093 TSE:4151 TSE:4528 SHSE:600436 SHSE:600867 SZSE:002422 MIL:REC BOM:500087 BOM:500302
Traded in other countries LILY34.Brazil LEL.UK
Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a pharmaceutical company with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta for cancer; Forteo for osteoporosis; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Cialis for erectile dysfunction. Also, Lilly holds a strong position in the animal healthcare market.

Ratios

Current vs industry vs history
PE Ratio (TTM) 37.28
Forward PE Ratio 20.41
N/A
PE Ratio without NRI 37.28
Price-to-Owner-Earnings 98.29
PB Ratio 12.42
PS Ratio 4.84
Price-to-Free-Cash-Flow 47.16
Price-to-Operating-Cash-Flow 21.43
EV-to-EBIT 28.90
EV-to-EBITDA 20.71
EV-to-Revenue 4.79
Shiller PE Ratio 34.82
Current Ratio 1.73
Quick Ratio 1.38
Days Inventory 243.81
Days Sales Outstanding 77.98
Days Payable 80.17

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 2.02
Dividend Payout Ratio 0.72
3-Year Dividend Growth Rate (Per Share) 4.00
Forward Dividend Yield % 2.24
N/A
Yield-on-Cost (5-Year) % 2.30
3-Year Share Buyback Rate 1.40

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 62.27
Price-to-Projected-FCF 3.15
Price-to-Median-PS-Value 1.80
Price-to-Graham-Number 10.09
Earnings Yield (Joel Greenblatt) % 3.46
Forward Rate of Return (Yacktman) % 0.03

More Statistics

Revenue (TTM) (Mil) $ 24,555.7
EPS (TTM) $ 3.09
Beta 0.54
Volatility % 16.81
52-Week Range $ 77.09 - 132.13
Shares Outstanding (Mil) 970.42

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 7
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy Y
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N